LHI0 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)4.62K
Market Cap
€12.54M
Enterprise Value€14.24
Total Cash (Recent Filing)€1.88M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta3.87
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,027,571,000
10 Day Avg. Volume1,000
30 Day Avg. Volume4,615
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-6.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetNo reported debt reduces fixed financial obligations and lowers exposure to refinancing or interest-cost pressure. That gives management greater flexibility to allocate available capital toward research and development, while providing some resilience if development timelines extend.
Positive Equity BasePositive shareholders’ equity provides a remaining capital base that is stronger than a balance-sheet deficit, giving the company some financial capacity while it advances its programs. Although equity has been volatile, its latest positive position modestly supports ongoing operations.
Regenerative Medicine FocusA focused regenerative-medicine and cell-therapy model gives the company exposure to potentially significant unmet medical needs in diabetes and Parkinson’s disease. If its programs advance successfully, this specialization could support differentiated products and a durable biotechnology platform.
Bears Say
No Reported RevenueThe absence of reported revenue means the business has not yet demonstrated commercial traction or an operating revenue base. This leaves future funding and value creation dependent on successful program development, regulatory progress, and eventual commercialization rather than established customer demand.
Persistent Net LossesPersistent and sizable net losses, including a larger loss in 2026, indicate that current activities are not yet economically self-sustaining. Continued losses can erode equity over time and increase the capital required to maintain development programs before any products generate revenue.
Ongoing Cash BurnNegative operating and free cash flow every year shows that the company continues to consume cash to fund operations rather than generate internal financing. Sustained burn limits self-funding capacity and makes continued execution increasingly dependent on preserving or obtaining external capital.
Living Cell Technologies News
LHI0 FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is €12.54M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 171 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Aug 27, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 2,027,571,000 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in DE:LHI0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:LHI0 Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Technical Analysis
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―